Content about Motor neurone disease

June 3, 2013
CVS/pharmacy supporting medical research for ALS cure via in-store fundraiser

CVS/pharmacy has announced the launch of its annual in-store Advancing Medical Research fundraising campaign to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS).

WOONSOCKET, R.I. — CVS/pharmacy has announced the launch of its annual in-store Advancing Medical Research fundraising campaign to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS).

May 10, 2013
Denovo Biomarkers, ALS-ETF to explore personalized medicine in amyotrophic lateral sclerosis

A biotech company and a non-profit organization are looking into new ways to treat patients with the devastating degenerative disorder commonly known as Lou Gehrig's disease.

SAN DIEGO — A biotech company and a nonprofit organization are looking into new ways to treat patients with the devastating degenerative disorder commonly known as Lou Gehrig's disease.

The ALS Emergency Treatment Fund and Denovo Biomarkers announced Friday a deal to explore the use of personalized medicine in treating patients with the disease, known medically as amyotrophic lateral sclerosis. The two said the approach could accelerate drug development in ALS and other life-threatening disorders.

November 1, 2012
Global MS market to reach $19.5 billion in 2017, report finds

The global market for treatments for neurodegenerative disorders will exceed $20 billion before the end of the decade, according to a new report.

FARMINGTON, Conn. – The global market for treatments for neurodegenerative disorders will exceed $20 billion before the end of the decade, according to a new report.

Global Information announced the availability of four research reports that analyze the global markets for treatments for syndromes of progressive ataxia and weakness disorders. According to GII, the global market for treatments was nearly $14 billion and is expected to reach $23.5 billion by 2017, after increasing at a five-year compound annual growth rate of 9.4%.

August 29, 2012
CVS/pharmacy-funded research points to new pathways, treatment strategy for ALS

In the battle to find a cure for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, scientists from Belgium have made a rare discovery: a new gene that influences survival time of ALS. The findings, reported in a recent issue of Nature Medicine, were funded in part by CVS/pharmacy and the ALS Therapy Alliance, a Boston-based nonprofit.

NEEDHAM, Mass. — In the battle to find a cure for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, scientists from Belgium have made a rare discovery: a new gene that influences survival time of ALS. The findings, reported in a recent issue of Nature Medicine, were funded in part by CVS/pharmacy and the ALS Therapy Alliance, a Boston-based nonprofit. The findings also confirm another recent study that identified the same pathway to finding a treatment for ALS.

May 16, 2010
Teva: Lou Gehrig’s disease treatment trial did not meet endpoints

An investigational drug made by Teva Pharmaceutical Industries was not effective in patients with Lou...